In 1956 our colleague, Dr. A. R. Martin,4 discovered in these laboratories that systemically administered griseofulvin produced dramatic cure in superficial mycotic infections of the guinea pig skin. It therefore became necessary to determine whether griseofulvin was safe enough to administer to man. This paper reports the investigations carried out to this end. These have already been briefly reported elsewhere (Paget and Walpole,5 1958).
All the griseofulvin used in these experiments was obtained from Messrs. Glaxo as a white crystalline powder. Animals dosed orally received appropriate doses as a 4% suspension of this material in 0.5% Tween 80. The doses were given by stomach tube once daily five days a week. For parenteral, and particularly for intravenous, administration it is necessary to produce a fine-particle-size suspension. For this purpose dry griseofulvin powder was finely ground in a pestle and mortar and then suspended in 0.5% Tween
PAGET GE, WALPOLE AL. The Experimental Toxicology of Griseofulvin. AMA Arch Derm. 1960;81(5):750–757. doi:10.1001/archderm.1960.03730050106018
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: